Fc receptor News and Research

RSS

Study observes correlation between COVID-19 mortality and autoantibodies in corticosteroid treated patients

Corticosteroid anti-inflammatory drugs have been applied to COVID-19 patients over the course of the pandemic, though the results are mixed. In a recent study, the outcomes for such patients are collated, demonstrating a striking correlation between the development of autoantibodies and mortality.

25 Mar 2021

Neutralizing antibodies to SARS-CoV-2 in mice depend on Fc effector function

A new study reports the essential nature of Fc-mediated functionalities in determining the efficacy of such antibodies.

24 Mar 2021

Are SARS-CoV-2 antibodies associated with disease enhancement?

As SARS-CoV-2 continues to wreak its havoc, antibodies that neutralize the virus and protect against infection have become an important focus of research. However, there is a concern as to whether these antibodies can actually enhance the disease.

6 Jan 2021

Early interferon therapy may mitigate COVID-19 severity

A recent review of COVID-19 therapies explores the utility of interferons in the battle against severe COVID-19, and concludes that they deserve further development.

26 Nov 2020

COVID-19 during pregnancy can cause placental inflammation and impaired immunity

A new study conducted by a team of researchers at Johns Hopkins University, USA, has observed how pregnant women infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) show stunted antiviral immune responses.

18 Nov 2020

Babies can acquire allergies from their mothers in the womb

Mothers can pass on allergies to offspring while they are developing in the womb and that is one reason why babies exhibit allergies early in life, according to a Singapore preclinical study.

10 Nov 2020

Soluble ACE2 microbody blocks SARS-CoV-2 entry into lung cells

A new study by researchers at NYU Langone Medical Center and Weill Cornell Medical College and published on the preprint server bioRxiv* in September 2020 reports the potential of an angiotensin-converting enzyme 2 (ACE2)-antibody Fc complex in a new format that seems to offer more significant inhibition of SARS-CoV-2.

21 Sep 2020

Optimal antibody combinations and Fc binding inhibit SARS-CoV-2 in vivo

A recent study by researchers at the University of North Carolina at Chapel Hill and The Rockefeller University and published on the preprint server bioRxiv in September 2020 shows that a combination of neutralizing antibodies with intact Fc effector function can effectively reduce the viral load and prevent infection.

17 Sep 2020

Study finds synthetic neutralizing/enhancing antibodies to SARS-CoV-2

A new study published on the preprint server bioRxiv in July 2020 reports the discovery of some antibody molecules that have powerful enhancing or neutralizing activity against the virus, in a library of synthetic antibodies. These hold the promise of being useful for the prevention or treatment of this illness.

30 Jul 2020

Dysfunctional T cells present at high levels in severe COVID-19

Now, a new study by researchers at Saarland University, Germany, and published on the preprint server medRxiv in July 2020 shows that there are higher levels of anti-SARS-CoV-2 T cells, which show significant alterations in the phenotype and function.

12 Jul 2020

Study assesses impact of anti-SARS-CoV-2 convalescent plasma in COVID-19 disease

The current COVID-19 pandemic is still very much active in most parts of the world. In the absence of effective antiviral drugs or vaccines, scientists are studying the use of blood plasma from convalescent COVID-19 patients, banking on its neutralizing antibody content.

25 Jun 2020

Novel ACE2-antibody fusion molecules show anti-SARS-CoV-2 activity

Now, in a new study published on the preprint server, bioRxiv researchers in the U.S. investigated a soluble version of ACE2 for SARS-CoV-2 viral neutralization activity.

17 Jun 2020

Turning autoimmunity drugs into anti-cancer treatments

Professor Mark Cragg speaks to News-Medical about his research which involves turning autoimmunity drugs into anti-cancer treatments.

11 Jun 2020

Maternal microbiota is a source of newborn immunity, shows study

Mother's milk has been long touted for its salutary effects on the newborn and its ability to shield infants from certain infections.

9 Jan 2020

Inhibition of a single enzyme may reduce heparin-induced thrombocytopenia

Heparin is widely used as an anticoagulant, but evokes in some patients a potentially life-threatening condition called HIT. Clinical scientists at Ludwig-Maximilians-Universitaet in Munich have now shown that inhibition of a single enzyme may markedly reduce this risk.

21 Dec 2019

Common cold virus could infect fetus via placenta

According to researchers, the common cold viruses are capable of infecting human placental cells and may thus transmit the infection to the fetus in the womb during pregnancy. The new study was published in the journal PLOS ONE, and provides the first concrete proof that this type of carriage is possible.

3 Dec 2019

Mother's dengue immunity influences the severity of Zika infection in infants

Researchers at Duke-NUS Medical School and their colleagues have identified a surprising interaction between dengue and Zika viruses that sheds lights on the significant fetal brain abnormalities linked to Zika virus.

1 Mar 2019

Novel imaging technique shows promise to detect, monitor and guide therapy for prostate cancer

An international group of researchers report success in mice of a method of using positron emission tomography scans to track, in real time, an antibody targeting a hormone receptor pathway specifically involved in prostate cancer.

1 Dec 2016

Antibody protection may help control infection caused by TB bacteria

A study led by investigators from the Ragon Institute of MGH, MIT and Harvard finds evidence that antibody protection may help control infection with the bacteria that causes tuberculosis (TB).

4 Oct 2016

New mouse model allows researchers to evaluate CD40-antibody drugs effectively

Cancer immunotherapies--drugs that work by making a patient's immune system better at spotting and destroying tumor cells--are increasingly generating headlines. A number of these drugs are now being used for the treatment of melanoma, lung, and kidney cancers, and are showing promise in clinical trials with other diseases as well.

3 Jun 2016